Search Results - "VanderLaan, Paul A"

Fine‐needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities by VanderLaan, Paul A.

“…Fine‐needle aspiration (FNA) and core needle biopsy (CNB) represent 2 of the most common minimally invasive tissue sampling modalities. Although similar in…”
Get full text

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma by Rangachari, Deepa, VanderLaan, Paul A, Shea, Meghan, Le, Xiuning, Huberman, Mark S, Kobayashi, Susumu S, Costa, Daniel B

“…Targeted somatic genomic analysis (EGFR, anaplastic lymphoma receptor tyrosine kinase gene [ALK], and ROS1) and programmed death ligand 1 (PD-L1) tumor…”
Get more information

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples by Rangachari, Deepa, To, Ciric, Shpilsky, Jason E, VanderLaan, Paul A, Kobayashi, Susumu S, Mushajiang, Mierzhati, Lau, Christie J, Paweletz, Cloud P, Oxnard, Geoffrey R, Jänne, Pasi A, Costa, Daniel B

“…Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-generation…”
Get more information

Molecular markers: Implications for cytopathology and specimen collection by VanderLaan, Paul A.

“…Cytologic specimens obtained through minimally invasive biopsy techniques are increasingly being used as principle diagnostic specimens for tumors arising in…”
Get full text

CT Manifestations of Tumor Spread Through Airspaces in Pulmonary Adenocarcinomas Presenting as Subsolid Nodules by de Margerie-Mellon, Constance, Onken, Allison, Heidinger, Benedikt H, VanderLaan, Paul A, Bankier, Alexander A

“…PURPOSE:The aim of this study was to identify potential computed tomography manifestations of pulmonary adenocarcinomas presenting as subsolid nodules and…”
Get full text

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer by Bahcall, Magda, Awad, Mark M, Sholl, Lynette M, Wilson, Frederick H, Xu, Man, Wang, Stephen, Palakurthi, Sangeetha, Choi, Jihyun, Ivanova, Elena V, Leonardi, Giulia C, Ulrich, Bryan C, Paweletz, Cloud P, Kirschmeier, Paul T, Watanabe, Masayuki, Baba, Hideo, Nishino, Mizuki, Nagy, Rebecca J, Lanman, Richard B, Capelletti, Marzia, Chambers, Emily S, Redig, Amanda J, VanderLaan, Paul A, Costa, Daniel B, Imamura, Yu, Jänne, Pasi A

“…MET inhibitors can be effective therapies in patients with exon 14 ( ex14) mutant non-small cell lung cancer (NSCLC). However, long-term efficacy is limited by…”
Get full text

The Growth Rate of Subsolid Lung Adenocarcinoma Nodules at Chest CT by de Margerie-Mellon, Constance, Ngo, Long H, Gill, Ritu R, Monteiro Filho, Antonio C, Heidinger, Benedikt H, Onken, Allison, Medina, Mayra A, VanderLaan, Paul A, Bankier, Alexander A

“…Background Confirming that subsolid adenocarcinomas show exponential growth is important because it would justify using volume doubling time to assess their…”
Get full text

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? by Sehgal, Kartik, Varkaris, Andreas, Viray, Hollis, VanderLaan, Paul A, Rangachari, Deepa, Costa, Daniel B

“…BackgroundHistological transformation of oncogene-driven lung adenocarcinoma to small cell lung cancer (SCLC) following treatment with tyrosine kinase…”
Get full text

Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology by Layfield, Lester J., Roy-Chowdhuri, Sinchita, Baloch, Zubair, Ehya, Hormoz, Geisinger, Kim, Hsiao, Susan J., Lin, Oscar, Lindeman, Neal I., Roh, Michael, Schmitt, Fernando, Sidiropoulos, Nikoletta, VanderLaan, Paul A.

“…The Papanicolaou Society of Cytopathology has developed a set of guidelines for respiratory cytology including indications for sputum examination, bronchial…”
Get full text

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors by Vasconcelos, Pedro E.N.S., Gergis, Carol, Viray, Hollis, Varkaris, Andreas, Fujii, Masanori, Rangachari, Deepa, VanderLaan, Paul A., Kobayashi, Ikei S., Kobayashi, Susumu S., Costa, Daniel B.

“…The EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation (∼5% to 6% of exon 20 insertions), which, at the structural and enzyme kinetic level, more…”
Get full text

Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: a single center analysis by DiStasio, Marcello, MD, PhD, Chen, Yigu, MPH, Rangachari, Deepa, MD, Costa, Daniel B., MD, PhD, Heher, Yael K., MD, MPH, VanderLaan, Paul A., MD, PhD

“…Abstract Introduction Molecular testing to identify targetable driver mutations is the standard of care for patients with advanced stage non-small cell lung…”
Get full text

The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio by Krane, Jeffrey F., VanderLaan, Paul A., Faquin, William C., Renshaw, Andrew A.

“…BACKGROUND: The Bethesda System (TBS) for reporting thyroid cytopathology introduced the atypia of undetermined significance/follicular lesion of undetermined…”
Get full text

Invariant Natural Killer T-Cells and Total CD1d Restricted Cells Differentially Influence Lipid Metabolism and Atherosclerosis in Low Density Receptor Deficient Mice by VanderLaan, Paul A, Reardon, Catherine A, Cabana, Veneracion G, Wang, Chyung-Ru, Getz, Godfrey S

“…Natural killer T (NKT) cells are a distinct subset of lymphocytes that bridge the innate and adaptive immune response and can be divided into type I invariant…”
Get full text

EGFR testing in advanced non-small-cell lung cancer, a mini-review by Sheikine, Yuri, MD, PhD, Rangachari, Deepa, MD, McDonald, Danielle C., NP, Huberman, Mark S., MD, Folch, Erik S., MD, MSc, VanderLaan, Paul A., MD, PhD, Costa, Daniel B., MD, PhD

“…Abstract Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor ( EGFR )…”
Get full text

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer by Sehgal, Kartik, Peters, Mary Linton B, VanderLaan, Paul A, Rangachari, Deepa, Kobayashi, Susumu S, Costa, Daniel B

Get more information

Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer by Folch, Erik, Yamaguchi, Norihiro, VanderLaan, Paul A, Kocher, Olivier N, Boucher, David H, Goldstein, Michael A, Huberman, Mark S, Kent, Michael S, Gangadharan, Sidharta P, Costa, Daniel B, Majid, Adnan

“…Adequate tumor acquisition is essential to identify somatic molecular alterations in non-small-cell lung cancer (NSCLC), such as epidermal growth factor…”
Get more information

Preoperative bronchial cytology for the assessment of tumor spread through air spaces in lung adenocarcinoma resection specimens by Medina, Mayra A., Onken, Allison M., Margerie‐Mellon, Constance, Heidinger, Benedikt H., Chen, Yigu, Bankier, Alexander A., VanderLaan, Paul A.

“…Background Tumor spread through air spaces (STAS), a significant prognostic indicator, has been described recently as a pattern of invasion in pulmonary…”
Get full text

Atypia of Undetermined Significance and Nondiagnostic Rates in The Bethesda System for Reporting Thyroid Cytopathology Are Inversely Related by VANDERLAAN, Paul A, RENSHAW, Andrew A, KRANE, Jeffrey F

“…There is substantial variation in the reported rates of different diagnostic categories in The Bethesda System for Reporting Thyroid Cytopathology (TBS)…”
Get full text

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors by Kobayashi, Ikei S., Shaffer, William, Viray, Hollis, Rangachari, Deepa, VanderLaan, Paul A., Kobayashi, Susumu S., Costa, Daniel B.

“…Mechanisms of resistance to EGFR exon 20 insertion mutation active inhibitors have not been extensively studied in either robust preclinical models or…”
Get full text

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors by Le, Xiuning, Desai, Neelam V, Majid, Adnan, Karp, Rebecca S, Huberman, Mark S, Rangachari, Deepa, Kent, Michael S, Gangadharan, Sidharta P, Folch, Erik, VanderLaan, Paul A, Costa, Daniel B

“…Highlights • EGFR mutations occur in some high-grade neuroendocrine lung cancers. • EGFR protein is not expressed in EGFR mutated neuroendocrine lung cancers…”
Get full text